• Cardiology, Diabetes & Nephrology
    • Cardiology, Diabetes & Nephrology – London
    • Cardiology, Diabetes & Nephrology – Brazil
    • Cardiology, Diabetes & Nephrology – Canada
    • The Hatter Cardiovascular Institute Horizon Meetings
    • The 19th Malvern Diabetic Foot Conference
    • Previous Events
      • CDNATL 2022 – London
      • CDNATL 2019 – London
      • CDNATL 2019 – Brazil
      • CDNATL 2018
      • CDNATL 2017
      • CDNATL 2016
      • CDNATL 2015
      • CDNATL 2014
      • CDATL 2013
      • CDATL 2012
      • NATL 2012
      • CDATL 2011
      • CDATL 2010
      • NATL 2010
      • CATL 2009
      • NATL 2009
  • Cell Therapy
    • Cell Therapy at the Limits 2022
  • Oncology
    • Previous Events
      • Accelerating Cancer Immunotherapy 2017
      • OATL 2016
      • OATL 2015
      • OATL 2014
      • OATL 2012
      • OATL 2011
      • OATL 2010
      • UCL Frontiers of Oncology 2019
        • Haematology
        • Melanoma
        • Urology
        • Women’s Health
        • Lung Cancer
        • Gastrointestinal Oncology
  • Multiple Sclerosis
    • Multiple Sclerosis at the Limits 2022
    • Multiple Sclerosis Nurses at the Limits 2022
    • Previous events
      • Multiple Sclerosis at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2019
      • MSATL 2018: Introduction
      • MSATL 2017: Introduction
  • About
    • Academic Founders
    • Independence
    • The Lancet
    • Support & Sponsorship
    • Delegate Invitations
  • Supporters
  • Archive
    • CDNATL 2019 – London
    • CDNATL 2019 – Brazil
    • Multiple Sclerosis at the Limits 2018
    • Multiple Sclerosis at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2019
    • Hatter Horizon Series
      • Horizon GP Programme 2019
      • Hatter Horizon Series 2019
      • Hatter Horizon Series 2018
      • Hatter Horizon Series 2017
    • Cardiology, Diabetes & Nephrology at the Limits 2018
    • Accelerating Cancer Immunotherapy 2017
    • Oncology at the Limits 2017

Professor Bart Vanhaesebroeck

Bart Vanhaesebroeck is Professor of Cell Signalling at the UCL Cancer Institute in London.

Following a PhD from Ghent University (Belgium), focusing on cytokine signalling and cell death, BV carried out postdoctoral studies with Mike Waterfield at the Ludwig Institute for Cancer Research, London where he was involved in the isolation of PI 3-kinase (PI3K) genes. These studies led to the realisation that PI3Ks form a family of related enzymes.

Our research aims to uncover the functions of these PI3K isoforms, both in normal physiology and in disease, and to understand their molecular mechanism of action.

We pioneered the use of ‘kinase knockin’ mice, in which a kinase is inactivated by germline mutation of a conserved ATP-binding residue in the kinase active site. This strategy provides a more adequate physiological model for the effects of kinase inhibitors than gene knock-out approaches.

We discovered the p110delta isoform of PI3K as a new drug target in inflammation, allergy, haematological malignancies and, most recently, in solid tumours. We have taken the characterization of p110delta ‘all the way’, from gene cloning, through to the development of the first mouse models, followed by the generation of p110delta inhibitors in a drug development programme with PIramed Ltd (purchased by Roche in 2008). Targeting p110delta has been the most successful clinical PI3K inhibitor development effort to date, which culminated in the approval in 2014 of the p110delta inhibitor Zydelig (Gilead) for the treatment of specific blood cancers. p110delta inhibitors are also being trialled in arthritis and allergy. Our recent work (Nature 2014:510:407) indicates that p110delta is also a target for immuno-stimulation in cancer, potentially widening the use of p110delta drugs from inflammation and haematological malignancies to immune-therapy of solid tumours.

An increasing focus of the laboratory is to model the aberrant PI3K activation as observed in disease, using physiologically-relevant genetic strategies in mice and cells. A focus of this work is on the p110alpha isoform of PI3K, which is frequently overactive in cancer and overgrowth syndromes, as a consequence of the presence of activating point mutations.

BV is an elected member of EMBO and of the UK Academy of Medical Sciences.

« Dr Alan Ashworth
Professor Alison Lloyd »

The 19th Malvern Diabetic Foot Conference
Wednesday, 11 - Friday, 13 May 2022, Malvern, UK

Cell Therapy at the Limits 2022
Monday, 27 & Tuesday, 28 June 2022, London, UK

Multiple Sclerosis Nurses
at the Limits

Friday, 16 & Saturday, 17 September 2022, London, UK

Multiple Sclerosis at the Limits
Monday, 19 & Tuesday, 20 September 2022, London, UK

Cardiology, Diabetes & Nephrology at the Limits Japan
Saturday 15th & Sunday 16th October 2022, Tokyo, Japan

Cardiology, Diabetes & Nephrology at the Limits Canada
Q3 2022, Toronto, Canada

Cardiology, Diabetes & Nephrology at the Limits Brazil
April & October 2022, Brazil

The Hatter Cardiovascular Institute Horizon GP Meeting
Wednesday, 9 November 2022
London, UK

The Hatter Cardiovascular Institute Horizon Meeting
Wednesday, 23 November 2022, London, UK

Cardiology, Diabetes & Nephrology at the Limits 2023
London,UK

  • Contact
  • The Lancet
  • UCL
  • UCT
  • Brigham & Women’s Hospital
  • The University of Campinas
© 2022 At the Limits Ltd.
This site uses cookies More info